These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 26681512)

  • 1. Improved synthesis of MC4-PPEA and the biological evaluation of its hydroxymethyl derivative.
    Sadrerafi K; Zargham EO; Lee MW
    Bioorg Med Chem Lett; 2016 Jan; 26(2):618-621. PubMed ID: 26681512
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors.
    Sadrerafi K; Mason EO; Lee MW
    Drug Des Devel Ther; 2018; 12():987-995. PubMed ID: 29731606
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-Based Design of Potent Nicotinamide Phosphoribosyltransferase Inhibitors with Promising in Vitro and in Vivo Antitumor Activities.
    Bai J; Liao C; Liu Y; Qin X; Chen J; Qiu Y; Qin D; Li Z; Tu ZC; Jiang S
    J Med Chem; 2016 Jun; 59(12):5766-79. PubMed ID: 27224875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SAR and characterization of non-substrate isoindoline urea inhibitors of nicotinamide phosphoribosyltransferase (NAMPT).
    Curtin ML; Heyman HR; Clark RF; Sorensen BK; Doherty GA; Hansen TM; Frey RR; Sarris KA; Aguirre AL; Shrestha A; Tu N; Woller K; Pliushchev MA; Sweis RF; Cheng M; Wilsbacher JL; Kovar PJ; Guo J; Cheng D; Longenecker KL; Raich D; Korepanova AV; Soni NB; Algire MA; Richardson PL; Marin VL; Badagnani I; Vasudevan A; Buchanan FG; Maag D; Chiang GG; Tse C; Michaelides MR
    Bioorg Med Chem Lett; 2017 Aug; 27(15):3317-3325. PubMed ID: 28610984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of potent and efficacious cyanoguanidine-containing nicotinamide phosphoribosyltransferase (Nampt) inhibitors.
    Zheng X; Baumeister T; Buckmelter AJ; Caligiuri M; Clodfelter KH; Han B; Ho YC; Kley N; Lin J; Reynolds DJ; Sharma G; Smith CC; Wang Z; Dragovich PS; Oh A; Wang W; Zak M; Wang Y; Yuen PW; Bair KW
    Bioorg Med Chem Lett; 2014 Jan; 24(1):337-43. PubMed ID: 24279990
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural and biochemical analyses of the catalysis and potency impact of inhibitor phosphoribosylation by human nicotinamide phosphoribosyltransferase.
    Oh A; Ho YC; Zak M; Liu Y; Chen X; Yuen PW; Zheng X; Liu Y; Dragovich PS; Wang W
    Chembiochem; 2014 May; 15(8):1121-30. PubMed ID: 24797455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carboranes increase the potency of small molecule inhibitors of nicotinamide phosphoribosyltranferase.
    Lee MW; Sevryugina YV; Khan A; Ye SQ
    J Med Chem; 2012 Aug; 55(16):7290-4. PubMed ID: 22889195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fragment-based design of 3-aminopyridine-derived amides as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Zhao G; Baumeister T; Bravo B; Giannetti AM; Ho YC; Hua R; Li G; Liang X; Ma X; O'Brien T; Oh A; Skelton NJ; Wang C; Wang W; Wang Y; Xiao Y; Yuen PW; Zak M; Zhao Q; Zheng X
    Bioorg Med Chem Lett; 2014 Feb; 24(3):954-62. PubMed ID: 24433859
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of 2,3-dihydro-1H-pyrrolo[3,4-c]pyridine-derived ureas as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Dragovich PS; Bair KW; Baumeister T; Ho YC; Liederer BM; Liu X; Liu Y; O'Brien T; Oeh J; Sampath D; Skelton N; Wang L; Wang W; Wu H; Xiao Y; Yuen PW; Zak M; Zhang L; Zheng X
    Bioorg Med Chem Lett; 2013 Sep; 23(17):4875-85. PubMed ID: 23899614
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of benzothiophene amides as potent inhibitors of human nicotinamide phosphoribosyltransferase.
    Chen W; Dong G; He S; Xu T; Wang X; Liu N; Zhang W; Miao C; Sheng C
    Bioorg Med Chem Lett; 2016 Feb; 26(3):765-768. PubMed ID: 26755394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of amides derived from 1H-pyrazolo[3,4-b]pyridine-5-carboxylic acid as potent inhibitors of human nicotinamide phosphoribosyltransferase (NAMPT).
    Zheng X; Bair KW; Bauer P; Baumeister T; Bowman KK; Buckmelter AJ; Caligiuri M; Clodfelter KH; Feng Y; Han B; Ho YC; Kley N; Li H; Liang X; Liederer BM; Lin J; Ly J; O'Brien T; Oeh J; Oh A; Reynolds DJ; Sampath D; Sharma G; Skelton N; Smith CC; Tremayne J; Wang L; Wang W; Wang Z; Wu H; Wu J; Xiao Y; Yang G; Yuen PW; Zak M; Dragovich PS
    Bioorg Med Chem Lett; 2013 Oct; 23(20):5488-97. PubMed ID: 24021463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Application of virtual screening to the discovery of novel nicotinamide phosphoribosyltransferase (NAMPT) inhibitors with potential for the treatment of cancer and axonopathies.
    Clark DE; Waszkowycz B; Wong M; Lockey PM; Adalbert R; Gilley J; Clark J; Coleman MP
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2920-2926. PubMed ID: 27158141
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and characterization of novel small-molecule inhibitors targeting nicotinamide phosphoribosyltransferase.
    Xu TY; Zhang SL; Dong GQ; Liu XZ; Wang X; Lv XQ; Qian QJ; Zhang RY; Sheng CQ; Miao CY
    Sci Rep; 2015 Jun; 5():10043. PubMed ID: 26040985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MC-PPEA as a new and more potent inhibitor of CLP-induced sepsis and pulmonary inflammation than FK866.
    Huang P; Lee MW; Sadrerafi K; Heruth DP; Zhang LQ; Maulik D; Ye SQ
    Drug Des Devel Ther; 2017; 11():629-641. PubMed ID: 28424540
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Minimizing CYP2C9 Inhibition of Exposed-Pyridine NAMPT (Nicotinamide Phosphoribosyltransferase) Inhibitors.
    Zak M; Yuen PW; Liu X; Patel S; Sampath D; Oeh J; Liederer BM; Wang W; O'Brien T; Xiao Y; Skelton N; Hua R; Sodhi J; Wang Y; Zhang L; Zhao G; Zheng X; Ho YC; Bair KW; Dragovich PS
    J Med Chem; 2016 Sep; 59(18):8345-68. PubMed ID: 27541271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retinal toxicity, in vivo and in vitro, associated with inhibition of nicotinamide phosphoribosyltransferase.
    Zabka TS; Singh J; Dhawan P; Liederer BM; Oeh J; Kauss MA; Xiao Y; Zak M; Lin T; McCray B; La N; Nguyen T; Beyer J; Farman C; Uppal H; Dragovich PS; O'Brien T; Sampath D; Misner DL
    Toxicol Sci; 2015 Mar; 144(1):163-72. PubMed ID: 25505128
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiotoxicity Associated with Nicotinamide Phosphoribosyltransferase Inhibitors in Rodents and in Rat and Human-Derived Cells Lines.
    Misner DL; Kauss MA; Singh J; Uppal H; Bruening-Wright A; Liederer BM; Lin T; McCray B; La N; Nguyen T; Sampath D; Dragovich PS; O'Brien T; Zabka TS
    Cardiovasc Toxicol; 2017 Jul; 17(3):307-318. PubMed ID: 27783203
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting NAMPT for Therapeutic Intervention in Cancer and Inflammation: Structure-Based Drug Design and Biological Screening.
    Pulla VK; Sriram DS; Soni V; Viswanadha S; Sriram D; Yogeeswari P
    Chem Biol Drug Des; 2015 Oct; 86(4):881-94. PubMed ID: 25850461
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of potent triazolylpyridine nicotinamide phosphoribosyltransferase (NAMPT) inhibitors bearing a 1,2,3-triazole tail group.
    Travelli C; Aprile S; Mattoteia D; Colombo G; Clemente N; Scanziani E; Terrazzino S; Alisi MA; Polenzani L; Grosa G; Genazzani AA; Tron GC; Galli U
    Eur J Med Chem; 2019 Nov; 181():111576. PubMed ID: 31400709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nicotinamide phosphoribosyltransferase inhibitors, design, preparation, and structure-activity relationship.
    Christensen MK; Erichsen KD; Olesen UH; Tjørnelund J; Fristrup P; Thougaard A; Nielsen SJ; Sehested M; Jensen PB; Loza E; Kalvinsh I; Garten A; Kiess W; Björkling F
    J Med Chem; 2013 Nov; 56(22):9071-88. PubMed ID: 24164086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.